BiotechTube
STALICLA

STALICLA

Geneva, Switzerland· Est.
stalicla.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $22.3M

Overview

STALICLA is a Geneva-based biotech founded in 2017, developing precision therapeutics for complex brain disorders, starting with Autism Spectrum Disorder (ASD). The company's core asset is its DEPI (Drug Efficacy Prediction Interface) platform, a biology-driven, AI-enhanced system that deconvolutes heterogeneous disorders into biologically defined subgroups to match them with targeted treatments. Its most advanced asset, STP1 (a combination of two approved drugs), is in Phase 2 trials for a specific ASD subgroup identified by DEPI. STALICLA represents a novel, data-driven approach to neuropsychiatry, aiming to deliver the first precision medicine for ASD.

Neurodevelopmental DisordersAutism Spectrum DisorderBrain Disorders

Technology Platform

DEPI (Drug Efficacy Prediction Interface) - a biology-driven, AI-enhanced platform that identifies biologically defined patient subgroups (biotypes) within heterogeneous brain disorders and matches them with targeted therapeutics.

Funding History

2
Total raised:$22.3M
Series A$17M
Seed$5.3M

Opportunities

The primary opportunity is to establish the first precision medicine treatment for Autism Spectrum Disorder, addressing a massive unmet need in a multi-billion dollar market with no approved core symptom therapies.
Successfully validating the DEPI platform creates a repeatable engine for de-risking drug development across a wide range of heterogeneous neuropsychiatric and neurodevelopmental disorders, enabling pipeline expansion and high-value partnerships.

Risk Factors

The key risk is clinical failure of the lead asset STP1 in Phase 2, which would challenge the core platform hypothesis.
Additional risks include navigating a novel regulatory path for a precision psychiatry treatment, future fundraising in a challenging biotech market, and eventual commercialization hurdles related to biomarker testing adoption and reimbursement.

Competitive Landscape

STALICLA operates in a nascent but emerging field of precision psychiatry. While large pharma has largely retreated from CNS drug development due to high failure rates, several biotechs (e.g., BlackThorn Therapeutics, Alto Neuroscience) are also applying data-driven approaches to patient stratification. STALICLA's direct focus on deconstructing ASD biology with its integrated DEPI platform and its advanced clinical program positions it as a unique and specialized player.

More companies in Switzerland →